KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Liabilities (2016 - 2025)

Nektar Therapeutics has reported Total Liabilities over the past 16 years, most recently at $190.6 million for Q4 2025.

  • Quarterly results put Total Liabilities at $190.6 million for Q4 2025, down 21.61% from a year ago — trailing twelve months through Dec 2025 was $190.6 million (down 21.61% YoY), and the annual figure for FY2025 was $190.6 million, down 21.61%.
  • Total Liabilities for Q4 2025 was $190.6 million at Nektar Therapeutics, down from $216.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for NKTR hit a ceiling of $475.7 million in Q3 2021 and a floor of $190.6 million in Q4 2025.
  • Median Total Liabilities over the past 5 years was $290.1 million (2023), compared with a mean of $322.9 million.
  • Biggest five-year swings in Total Liabilities: surged 40.87% in 2021 and later fell 26.27% in 2023.
  • Nektar Therapeutics' Total Liabilities stood at $437.7 million in 2021, then decreased by 21.41% to $344.0 million in 2022, then decreased by 22.36% to $267.0 million in 2023, then fell by 8.96% to $243.1 million in 2024, then fell by 21.61% to $190.6 million in 2025.
  • The last three reported values for Total Liabilities were $190.6 million (Q4 2025), $216.3 million (Q3 2025), and $231.7 million (Q2 2025) per Business Quant data.